According to NICE guidance, SGLT2 inhibitors are generally prioritised for patients with established cardiovascular disease, while GLP-1 receptor agonists like semaglutide are recommended based on glycaemic control and weight management criteria
Brief Bioinform 19(1):111
[DOI] [PubMed] [Google Scholar] 22.Benathan M, Virador V, Furumura M, Kobayashi N, Panizzon RG, Hearing VJ
To protect skin health, choose wisely based on evidence
Assessments are a one-time cost and usually are completed in 3-4 weeks
Moreover, the SUSTAIN trials, which studied the effects of semaglutide in those with T2DM, also demonstrated significant improvement in risk factors, with a substantial 26% relative reduction in cardiovascular events such as nonfatal myocardial infarction and stroke [13,14,29]